SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bikle DD, Pillai S. Vitamin D, calcium, and epidermal differentiation. Endocr Rev. 1993; 14: 319.
  • 2
    Reichekl H. Koeffler HP, Norman AW. The role of vitamin D endocrine system in health and disease. N Engl J Med. 1989; 320: 980991.
  • 3
    McElwain MC, Dettlebach MA, Modezelewski RA, et al. Antiproliferative effects in vitro and in vivo of 1,25-dihydroxyvitamin D3 and a vitamin D3 analog in a squamous cell carcinoma model system. Mol Cell Diff. 1995; 3: 3150.
  • 4
    Getzenberg RH, Light BW, Lapco PE, et al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology. 1997; 50: 9991006.
  • 5
    Mangelsdorf DJ, Koeffler HP, Donaldson CA, Pike JW, Haussler MR. 1,25-Dihydroxyvitamin D3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells. J Cell Biol. 1984; 98: 391398.
  • 6
    Colston KW, Chander SK, Mackay AG, Coombes RC. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol. 1992; 44: 693702.
  • 7
    Shabahang M, Buras RR, Davoodi F, et al. Growth inhibition of HT-29 human colon cancer cells by analogues of 1,25-dihyroxyvitamin D3. Cancer Res. 1994; 54: 40574064.
  • 8
    Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res. 1994; 54: 805810.
  • 9
    McGuire TF, Trump DL, Johnson CS. Vitamin D3-induced apoptosis of murine squamous cell carcinoma cells: selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J Biol Chem. 2001; 276: 2636526373.
  • 10
    Zhou JY, Norman AW, Chen DL. 1,25-dihydroxy-16-ene-23-yne-vitamin D3 prolongs survival time of leukemic mice. Proc Natl Acad Sci U S A. 1990; 87: 39293932.
  • 11
    Modzelewski RA. Apoptotic effects of paclitaxel and calcitriol in rat Dunning MLL and human PC-3 prostate tumor cells in vitro. Proc Am Assoc Cancer Res. 1999; 40: 580.
  • 12
    Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump DL, Johnson CS. 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21 (Waf1/Cip1) in vitro and in vivo. Cancer Res. 1999; 59: 26442649.
  • 13
    Yu WD, McElwain MC, Modzelewski RA, et al. Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. J Natl Cancer Inst. 1998; 90: 134141.
  • 14
    Bernardi RJ, Trump DL, Yu W-D, McGuire TF, Hershberger PA, Johnson CS. Combination of 1alpha,25-dihydroxyvitamin D3 with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling. Clin Cancer Res. 2001; 7: 41644173.
  • 15
    Klein RG, Arnaud SB, Gallagher JC, Deluca HF, Riggs BL. Intestinal calcium absorption in exogenous hypercortisolism. Role of 25-hydroxyvitamin D and corticosteroid dose. J Clin Invest. 1997; 60: 253259.
  • 16
    Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL. A phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res. 1999; 5: 13391345.
  • 17
    Gross C, Stamey T, Hancock S, Feldman D. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol) J Urol. 1998; 159: 20352039.
  • 18
    Mellibovsky L, Diez A, Perez-Vila E, et al. Vitamin D treatment in myelodysplastic syndromes. Br J Haematol. 1998; 100: 516520.
  • 19
    Munker R, Kobayashi T, Elstner E, et al. A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia. Blood. 1996; 88: 22012209.
  • 20
    Osborn JL, Schwartz GG, Smith DC, Bahnson R, Day R, Trump DL. phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol. 1995; 1: 195198.
  • 21
    Beer TM, Munar M, Henner WD. A phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer. 2001; 91: 24312439.
  • 22
    Morris MJ, Smaletz O, Solit D, et al. High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma. Cancer. 2004; 100: 18681875.
  • 23
    Muindi JR, Peng Y, Potter DM, et al. Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther. 2002; 72: 648659.
  • 24
    Beer TM, Lemmon D, Lowe BA, Henner WD. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer. 2003; 97: 12171224
  • 25
    Muindi JR, Modzelewski RA, Peng Y, Trump DL, Johnson CS. Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses. Oncology. 2004; 66: 6266.
  • 26
    Muindi JR, Potter DM, Peng Y, Johnson CS, Trump DL. Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: comparison with caplet formulation. Cancer Chemother Pharmacol. 2005; 56: 492496.
  • 27
    Beer TM, Javle M, Henner D, et al. Pharmacokinetics (PK) and tolerability of a DN-101, a new formulation of calcitriol, in patients with cancer. Proc Am Assoc Cancer Res. 2004; 45: 91
  • 28
    Beer TM, Ryan CW, Venner PM, et al. Interim results from ASCENT: a double-blinded randomized study of DN-101 (high dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC). Proc Am Soc Clin Oncol. 2005; 23(16S): 382.
  • 29
    Morioka M, Kobayashi T, Furukawa Y, et al. Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone. Urol Int. 2002; 68: 105
  • 30
    Saika T, Kusaka N, Tsushima T, et al., Urological Cancer Collaborating Group. Treatment of androgen-independent prostate cancer with dexamethasone: a prospective study in stage D2 patients. Int J Urol. 2001; 8: 290294.
  • 31
    Nishimura K, Nonomura N, Yasunaga Y, et al. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer. 2000; 89: 25702576.
  • 32
    Glode LM, Barqawi A, Crighton F, Crawford ED, Kerbel R. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer. 2003; 98: 15591561.
  • 33
    Harris KA, Weinberg V, Bok RA, Kakefuda M, Small EJ. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol. 2002; 168: 542545
  • 34
    Koutsilieris M, Mitsiades CS, Bogdanos J, et al. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Clin Cancer Res. 2004; 10: 43984405.
  • 35
    Weitzman AL, Shelton G, Zuech N, et al. Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. J Urol. 2000; 163: 834837.
  • 36
    Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer. J Clin Oncol. 1999; 17: 25062513.
  • 37
    Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol. 1989; 7: 590597.
  • 38
    Small EJ, Marshall ME, Reyno L, et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing Suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol. 2000; 18: 14401450.
  • 39
    Storlie JA, Buckner JC, Wiseman GA, Burch PA, Hartmann LC, Richardson RL. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer. 1995; 76: 96100.